Tag: Therapy

Digital MSK startup IncludeHealth scores $11M and more digital health fundings

Digital MSK startup IncludeHealth scores $11M and more digital health fundings

MobiHealthNews

Digital musculoskeletal (MSK) health company IncludeHealth announced it had raised $11 million in a funding round led by CincyTech with participation from Tamarind Hill and other investors.The company said it would use the funds to expand MSK-OS, its virtual care platform for delivering musculoskeletal care and physical therapy. Late last year, IncludeHealth announced a partnership with Yale New Haven Health System to offer a hybrid MSK care model for the system’s patients using the platform. 
In addition to the funding round, the startup said it had hired Ray Shealy as COO and added Grant Koster, who served as senior vice president of…

Continue Reading
FemTech: Joi Women’s Wellness Launches Nationwide

FemTech: Joi Women’s Wellness Launches Nationwide

HIT Consultant

What You Should Know:– Joi Women’s Wellness (Joi), a modern, femtech proactive approach to women’s health care, today announced the company’s official nationwide launch and availability of its hormone optimization and peptide therapy treatments, as well as the introduction of a new telehealth platform that provides a goals-based, customizable experience to help women own their health journey and manage the hormone and age–related changes to their bodies.– Joi offers health coaching and tailored treatments to help women feel their best from the inside out.Customized Wellness Treatments and Telehealth CoachingNearly half of women aged 30 to 60 have experienced symptoms of hormonal imbalance…

Continue Reading
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies

MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies

MedCity News

A slew of biotech companies are pursuing research that could overcome limitations of current cell therapies. Startup creator Replay has a new subsidiary pushing toward the front of the pack with a therapeutic candidate on track to start its first human test this summer—about one year after Replay emerged from stealth. It owes this rapid progress to a cell therapy pioneer’s technology that has already been de-risked by a big pharmaceutical company.
Replay calls itself a genome writing company. With operations split between San Diego and London, the private equity-backed business launched last July with $55 million and a suite of technologies…

Continue Reading
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

MedCity News

G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…

Continue Reading